NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - May 23, 2013) - BrainStorm Cell Therapeutics (
Topics discussed by Mr. Natanson include an update on the Company's NurOwn™ stem cell technology and its use in current and upcoming clinical trial activities. Specifically, Mr. Natanson discussed the very encouraging observations in the Company's recently completed Phase I/II trial, advances in the ongoing Phase IIa clinical trial and plans for the upcoming Phase II trial, expected to begin later this year in the U.S. at sites including Massachusetts General Hospital, UMass Hospital and the Mayo Clinic.
During the interview Mr. Natanson commented, "As far as companies in this field go, I think we've progressed more quickly than anyone, having successfully completed a Phase I trial in only a year and a half, and moved ahead immediately to Phase II, which should conclude later this year. To achieve all this in only 2 1/2 years is extremely fast. We hope to run our upcoming US trial at an equally fast pace, as we feel we are in a race to beat this disease and get our product to the market as quickly as possible."
About The Wall Street Analyst
The Wall Street Analyst conducts unbiased, unfiltered and candid interviews with management of publicly traded companies to unlock possible investment opportunities before the rest of the market discovers them. The WSA's staff of writers, analysts, publishers, producers, market researchers and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock and its audience consists of retail and institutional investors, analysts, fund managers and members of the financial press. For more information, visit www.thewallstreetanalysts.com.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics, Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.
Safe Harbor Statement -- Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics, Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
- Health Care Industry
- Investment & Company Information
- Cell Therapeutics